BiotechTube

Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kg

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Fungal Infection

Conditions

Invasive Fungal Infection

Trial Timeline

Feb 22, 2022 → Dec 31, 2026

NCT ID
NCT04665037

About Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kg

Posaconazole IV 6 mg/kg + Posaconazole PFS 6 mg/kg is a phase 2 stage product being developed by Merck for Invasive Fungal Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04665037. Target conditions include Invasive Fungal Infection.

What happened to similar drugs?

10 of 20 similar drugs in Invasive Fungal Infection were approved

Approved (10) Terminated (2) Active (9)
✅MicafunginAstellas PharmaApproved
✅caspofunginMerckApproved
✅SOC +Posaconazole 18 MG/ML (milligram/milliliter)MerckApproved
✅Caspofungin + Normal SalineMerckApproved
✅Ambisome + caspofunginGilead SciencesApproved
✅13-valent Pneumococcal conjugate vaccinePfizerApproved
✅voriconazolePfizerApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04665037Phase 2Recruiting

Competing Products

20 competing products in Invasive Fungal Infection

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
39
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
42
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPre-clinical
26
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Pudexacianinium chlorideAstellas PharmaPhase 2
35
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
26
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
35
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
MicafunginAstellas PharmaPre-clinical
26
Micafungin + PlaceboAstellas PharmaPhase 3
32
MicafunginAstellas PharmaApproved
35
Olorofim + AmBisome®ShionogiPhase 3
44
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
44
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
47